GOVX · GeoVax Labs, Inc.
What's happening
- GOVX is up 1.86% today, trading at $0.23. — Live quote
- It's trading within 3% of its 52-week low ($0.22). (Finnhub fundamentals)
- Volume today (424) is well below its 3-month average of 694,680. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.97 actual vs. $-2.94 estimated (+67.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (8 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 6.4% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-09-10; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -403.8%. Finnhub fundamentals ↗
- Trailing 52-week price return is -98.5%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on GOVX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$4.4M | -$5.3M | -$6.4M | -$5.4M | -$5.4M | -$5.9M | -$5.1M | -$5.9M |
| Net income | -$4.4M | -$5.3M | -$6.3M | -$5.4M | -$5.4M | -$5.8M | -$5.1M | -$5.9M |
| EPS (basic) | $-0.97 | $-2.62 | $-0.31 | $-8.74 | $-11.20 | $-0.91 | $-1.99 | $-2.47 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $4.6M | $3.0M | $6.3M | $6.7M | $5.4M | $10.8M | $8.2M | $11.1M |
| Total liabilities | $2.9M | $2.5M | $2.5M | — | — | — | $3.1M | — |
| Stockholders' equity | $1.8M | $493.8K | $3.8M | $4.9M | $2.8M | $7.9M | $5.0M | $8.5M |
| Total current assets | $4.2M | $2.4M | $5.3M | $6.5M | $5.1M | $10.6M | $7.9M | $10.9M |
| Total current liabilities | $2.7M | $2.3M | $1.9M | $1.8M | $2.5M | $2.9M | $3.1M | $2.6M |
| Cash & equivalents | $3.1M | $1.3M | $3.1M | $5.0M | $3.1M | $7.4M | $5.5M | $8.6M |
| Accounts receivable | — | — | $0 | $0 | $532.8K | $1.5M | $659.4K | $547.6K |
| Property, plant & equipment | $84.7K | $96.8K | $108.8K | $127.1K | $143.9K | $149.9K | $150.0K | $171.6K |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | $69.9K | $69.9K | $86.9K | $86.9K | $71.0K | $71.0K | $71.0K | $71.0K |
| Accounts payable | $1.8M | $1.4M | $790.8K | $976.4K | $1.8M | $2.4M | $1.8M | $2.1M |
| Accrued liabilities | $724.7K | $663.2K | $882.8K | $847.8K | $699.1K | $532.3K | $1.3M | $460.2K |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $7.4K | $2.8K | $1.7K | $29.7K | $15.9K | $13.8K | $421 | $8.6K |
| Retained earnings | -$160.5M | -$156.1M | -$150.8M | -$146.4M | -$140.1M | -$134.7M | -$129.4M | -$121.1M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.7M | -$3.5M | -$5.0M | -$6.2M | -$4.3M | -$6.0M | -$7.8M | -$9.3M |
| Investing cash flow | $0 | $0 | $0 | $0 | -$10.7K | -$16.9K | $0 | -$20.7K |
| Financing cash flow | $5.5M | $1.7M | $3.0M | $8.1M | $209 | $7.9M | $4.7M | $16.3M |
| Free cash flow | -$3.7M | -$3.5M | -$5.0M | -$6.2M | -$4.3M | -$6.0M | -$7.8M | -$9.3M |
| Capital expenditures | $0 | $0 | $0 | $0 | $10.7K | $16.9K | $0 | $20.7K |
| Depreciation & amortization | $12.1K | $12.1K | $18.2K | $16.8K | $16.8K | $16.9K | $21.6K | $30.4K |
| Share-based compensation | $163.7K | $219.3K | $252.1K | $277.5K | $292.7K | $292.7K | $139.3K | $129.9K |
| Change in accounts receivable | — | — | — | — | — | — | — | $246.9K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$21.6M | -$25.1M | -$26.7M | -$14.0M | -$18.7M |
| Net income | -$21.5M | -$25.0M | -$26.0M | -$14.0M | -$18.6M |
| EPS (basic) | $-22.40 | $-120.46 | $-14.29 | $-12.39 | $-3.04 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $6.3M | $8.2M | $9.3M | $31.3M | $11.8M |
| Total liabilities | $2.5M | $3.1M | — | $4.7M | $7.4M |
| Stockholders' equity | $3.8M | $5.0M | $5.8M | $26.6M | $4.4M |
| Total current assets | $5.3M | $7.9M | $7.9M | $28.9M | $11.6M |
| Total current liabilities | $1.9M | $3.1M | $3.5M | $4.7M | $5.4M |
| Cash & equivalents | $3.1M | $5.5M | $6.5M | $27.6M | $11.4M |
| Accounts receivable | $0 | $659.4K | $0 | — | — |
| Property, plant & equipment | $108.8K | $150.0K | $209.7K | $234.9K | $156.9K |
| Intangible assets | — | — | — | — | — |
| Other non-current assets | $86.9K | $71.0K | $1.2M | $2.2M | $11.0K |
| Accounts payable | $790.8K | $1.8M | $2.8M | $1.7M | $2.1M |
| Accrued liabilities | $882.8K | $1.3M | $716.9K | $3.0M | $3.4M |
| Other non-current liabilities | — | — | — | $0 | $2.0M |
| Common stock & paid-in capital | $1.7K | $421 | $2.0K | $1.8K | $6.4K |
| Retained earnings | -$150.8M | -$129.4M | -$104.4M | -$78.4M | -$64.4M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$21.5M | -$24.7M | -$25.2M | -$19.0M | -$11.2M |
| Investing cash flow | -$27.6K | -$20.7K | -$48.9K | -$134.3K | -$47.7K |
| Financing cash flow | $19.1M | $23.8M | $4.1M | $35.4M | $12.8M |
| Free cash flow | -$21.5M | -$24.7M | -$25.2M | -$19.2M | -$11.2M |
| Capital expenditures | $27.6K | $20.7K | $48.9K | $134.3K | $47.7K |
| Depreciation & amortization | $68.8K | $95.4K | $74.2K | $56.3K | $38.5K |
| Share-based compensation | $1.1M | $528.6K | $1.1M | $902.1K | $370.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding GOVX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-04-10 to 2025-10-17
Recent transactions
- Most recent: SPENCER JOHN N JR (Director) — Open market purchase of 10,000 shares on 2025-10-17.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| SPENCER JOHN N JR | Director | Open market purchase | 2025-10-17 | 10,000 |
| McKee Kelly T. Jr. | Chief Medical Officer | Open market purchase | 2025-08-07 | 1,107 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2025-10-17 | SPENCER JOHN N JR | Director | Open market purchase | 10,000 | $0.55 |
| 2025-08-07 | McKee Kelly T. Jr. | Chief Medical Officer | Open market purchase | 1,107 | $0.67 |
| 2025-04-10 | SPENCER JOHN N JR | Director | Open market purchase | 10,000 | $0.98 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:30 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-10 | 8-K | 2026-09-10 | View on SEC.gov → |
| 2026-08-28 | 8-K | 2026-08-27 | View on SEC.gov → |
| 2026-08-28 | 8-K | 2026-08-25 | View on SEC.gov → |
| 2026-07-27 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-27 | 8-K | 2026-07-27 | View on SEC.gov → |
| 2026-07-10 | 8-K | 2026-07-07 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-17 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-17 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-17 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-17 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-17 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-17 | View on SEC.gov → |
Recent news
Headlines about GOVX (GeoVax Labs, Inc.). Links open the publisher — we don’t host full articles.
-
GeoVax Labs Inc (NASDAQ: GOVX) Share Price, GOVX Stock News, GOVX Share Price & Updates
kalkine.ca · 2026-10-20 -
GeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026
Yahoo Finance · 2026-10-06 -
GeoVax Highlights Likely Sustained Clade Ib Mpox Transmission in the United States
Yahoo Finance · 2026-09-29 -
GeoVax Next-Generation MVA Vaccine Demonstrates Durable Single-Dose Protection in Preclinical Models
Yahoo Finance · 2026-09-21 -
GeoVax and CEPI Enter Agreement to Utilize CEPI Centralised Laboratory Network to Support GEO-MVA Phase 3 Trial
Yahoo Finance · 2026-09-14 -
GeoVax Provides Nasdaq Listing Update and Reaffirms Focus on Advancing Strategic Priorities
Yahoo Finance · 2026-09-10 -
GeoVax Welcomes Launch of Global Mpox Vaccine Stockpile, Highlights GEO-MVA Readiness to Support Diversified Global Supply
Yahoo Finance · 2026-09-09 -
GeoVax Advances GEO-MVA Toward Pivotal Phase 3 Study Implementation
Yahoo Finance · 2026-08-25
No headlines in this category right now — try “All”.